AlzeCure's Alzheimer's project NeuroRestore ACD856 granted an additional patent

Published: 29-Feb-2024

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain such as BDNF and NGF

AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, today announced that the patent offices seven countries have granted patents for ACD856, which is being developed against Alzheimer's and other disorders with cognitive impairment.

"This further strengthens the patent portfolio for ACD856 and is an important part of our continued strategic patent work with the NeuroRestore program where the goal is to build global IP protection for the molecule," said Gunnar Nordvall, Head of Chemistry and IP på AlzeCure Pharma.

The company's patent application for ACD856 has now also been granted in China, India, South Africa, Israel, Hong Kong and Mexico. 

The patent numbers are ZL2019800147986, IN432151, ZA2020/04220, IL276624, HK40033844 and MX402512, respectively, and the patents are expected to provide protection until 2039. Previously, ACD856 has been granted patent protection in the USA, Japan and Europe.

AlzeCure’s CEO Martin Jönsson, explained: "Expanded patent coverage strengthens the commercial opportunities for ACD856, especially when combined with the positive clinical data we previously obtained. Furthermore, ACD856 is targeted at treating Alzheimer's and depression, areas of very high unmet medical need." 

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition. 

Previous preclinical studies have shown that AlzeCure's drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions.

AlzeCure completed phase I clinical studies with ACD856 in 2022, where both good safety and tolerability were demonstrated in humans, but also that the drug candidate crossed the blood-brain barrier and that the substance activated parts of the brain that are central to both cognition and depression treatment.

New preclinical results also show potential neuroprotective and disease-modifying effects with these substances, which can be very significant for the project.

 

 

Trending Articles

You may also like